CD274 and melanoma: Several monoclonal antibodies (mAbs) directed against programmed cell death protein-1 ligand (PD-L1) and PD-1 have demonstrated clinical benefit in patients with melanoma, Hodgkin's lymphoma, lung and bladder carcinomas, and several other tumor types [1–5].